middle.news
Nyrada Doses First Patient in Xolatryp Phase IIa Heart Attack Trial
8:44am on Monday 27th of July, 2026 AEST
•
Biotechnology
Read Story
Nyrada Doses First Patient in Xolatryp Phase IIa Heart Attack Trial
8:44am on Monday 27th of July, 2026 AEST
Key Points
First patient dosed in Phase IIa PROTECT-MI trial
Multiple Australian hospital sites activated for recruitment
Preclinical studies show anti-tumour and cardioprotective potential
US patent allowance received, grant expected soon
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nyrada (ASX:NYR)
OPEN ARTICLE